COGT COGENT BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, COGENT BIOSCIENCES INC reported revenue of n/a, net income of −$96.4M and diluted EPS of −$0.52; for the fiscal year ended December 2025 revenue was n/a.
COGT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$333M, net income −$329M (margin n/a), EPS −$2.16
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$276M, net income −$256M (margin n/a), EPS −$1.94
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$208M, net income −$192M (margin n/a), EPS −$1.94
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$148M, net income −$140M (margin n/a), EPS −$1.73
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$75.6M, net income −$72.3M (margin n/a), EPS −$1.87
COGT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$96.4M, EPS −$0.52
- Quarter ended Mar 31, 2026: revenue n/a, net income −$97.4M, EPS −$0.53
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$102M, EPS −$0.61
- Quarter ended Sep 30, 2025: revenue n/a, net income −$80.9M, EPS −$0.50
- Quarter ended Jun 30, 2025: revenue n/a, net income −$73.5M, EPS −$0.53
- Quarter ended Mar 31, 2025: revenue n/a, net income −$72.0M, EPS −$0.52
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$67.9M, EPS −$0.50
- Quarter ended Sep 30, 2024: revenue n/a, net income −$70.6M, EPS −$0.52
- Quarter ended Jun 30, 2024: revenue n/a, net income −$59.0M, EPS −$0.43
- Quarter ended Mar 31, 2024: revenue n/a, net income −$58.3M, EPS −$0.49
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$54.4M, EPS −$0.16
- Quarter ended Sep 30, 2023: revenue n/a, net income −$55.4M, EPS −$0.64
- Quarter ended Jun 30, 2023: revenue n/a, net income −$44.1M, EPS −$0.59
- Quarter ended Mar 31, 2023: revenue n/a, net income −$38.6M, EPS −$0.55
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$39.6M, EPS $0.16
- Quarter ended Sep 30, 2022: revenue n/a, net income −$35.1M, EPS −$0.50
- Quarter ended Jun 30, 2022: revenue n/a, net income −$34.9M, EPS −$0.71
- Quarter ended Mar 31, 2022: revenue n/a, net income −$30.6M, EPS −$0.68
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$24.9M, EPS −$0.62
- Quarter ended Sep 30, 2021: revenue n/a, net income −$19.1M, EPS −$0.48
COGT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$264M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$208M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$154M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$119M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$58.8M, share buybacks n/a
COGT balance sheet
- Jun 30, 2026: cash $181M, total assets $835M, total liabilities $302M, shareholders' equity $532M
- Mar 31, 2026: cash $241M, total assets $903M, total liabilities $295M, shareholders' equity $608M
- Dec 31, 2025: cash $312M, total assets $938M, total liabilities $301M, shareholders' equity $636M
- Sep 30, 2025: cash $125M, total assets $426M, total liabilities $123M, shareholders' equity $302M, long-term debt $44.3M
- Jun 30, 2025: cash $128M, total assets $275M, total liabilities $120M, shareholders' equity $155M, long-term debt $43.9M
- Mar 31, 2025: cash $126M, total assets $284M, total liabilities $64.8M, shareholders' equity $219M
- Dec 31, 2024: cash $98.2M, total assets $328M, total liabilities $71.6M, shareholders' equity $256M, long-term debt $0
- Sep 30, 2024: cash $97.0M, total assets $384M, total liabilities $69.4M, shareholders' equity $315M
Is COGT profitable?
No. COGENT BIOSCIENCES INC lost $377M over the last four quarters.
What is COGT's EPS?
Diluted earnings per share over the last four quarters were −$2.16; −$0.52 in the latest quarter.